Butenafine drug use

Butenafine is an antifungal active ingredient of the Benzylamine group. The drug is usually prepared in the form of a topical skin cream with a concentration of 1%.
Butenafine is a synthetic Benzylamine derivative with a similar mechanism of action and structure to Allylamine. The drug inhibits Ergosterol synthesis and increases the concentration of squalene, leading to toxicity inside fungal cells. Butenafine has an in vitro fungicidal effect against M.furfur and dermatophytes, but has a fungicidal effect against Candida albicans strains.
After application, the concentration of Butenafine with fungicidal effect is maintained on the skin and especially for 72 hours. Butenafine when applied topically also has anti-inflammatory activity.

Butenafine topical (for the skin) is used to treat skin infections, pruritus, and ringworm infections: Treatment of tinea corporis (ringworm) and ringworm caused by Epidermophyton floccosum, Trichophyton mentagrophytes, T. rubrum.. . cause;
Available for self-purchase Butenafine for the treatment of tinea versicolor, tinea versicolor; Do not use Butenafine for scalp or nail infections. Topical antifungal butenafine is usually effective for the treatment of uncomplicated tinea versicolor or ringworm. Oral antifungals may be necessary when tinea versicolor is widespread, fungal folliculitis, chronic infection or unresponsive to topical doses, immunocompromised patients due to comorbidities, or due to concurrent therapy.
Contraindicated in case of hypersensitivity to Butenafine drug or to any component of the preparation.

3.1. Dosage Dosage of Butenafine drug for adults:
Treatment of foot fungus: Apply an appropriate amount of Butenafine to the skin to be treated and the surrounding skin, 1 time a day for 4 weeks; Tinea capitis: Apply an appropriate amount of Butenafine to the area to be treated and the surrounding skin, once daily for 2 weeks, depending on the condition. Inguinal and upper thigh: Apply an appropriate amount of Butenafine to the treatment area and surrounding skin, once a day for 2 weeks depending on the condition of the disease. The dose and duration of Butenafine treatment depend on the type of infection acquired. Do not apply more Butenafine or use it for longer than prescribed because this can increase the risk of side effects. If the patient does not improve clinically after treatment, the diagnosis and butenafine therapy should be re-evaluated.
Dosage of Butenafine for children 12 years and older: Use the same as the adult dose. Do not use Butenafine in children under 12 years of age without information; Patients with renal failure: Do not use oral Butenafine for patients with Clcr < 50 ml/min; Hepatic impairment: No dose reduction of Butenafine is required. 3.2. Directions For external use, avoid contact with eyes, nose, mouth and other mucous membranes. Apply a thin layer of Butenafine to and around the affected area, massaging gently, usually 1-2 times daily.
Clean affected areas with soap and water, then dry completely before applying Butenafine, can be applied after bathing. Gently massage Butenafine into affected areas, wash hands after use. Do not use bandages or wraps after applying Butenafine.

Local effects: Butenafine causes severe blistering, itching, redness, peeling, dryness, swelling, or skin irritation. Side effects of Butenafine are less common: Contact dermatitis, erythema, irritation and itching.

Use caution when administering Butenafine to patients with hypersensitivity to allylamine antifungals (eg, Naftifine, terbinafine) because cross-sensitization may occur. Do not use Butenafine to treat scalp or nail infections. Avoid contact of Butenafine with eyes or other mucous membranes. If eye contact occurs, flush immediately with large amounts of water and consult a physician if eye irritation persists. Avoid covering the area where Butenafine is applied; Perform direct microscopic examination of infected outer epidermal tissue in potassium hydroxide (KOH) solution or culture examination with appropriate media prior to initiation of Butenafine treatment; If irritation or sensitivity to Butenafine occurs, discontinue the drug and initiate appropriate therapy. Pregnant women: There are no studies when using Butenafine in pregnant women, so it is better to avoid using Butenafine for this population. Lactation: There have been no studies on the use of Butenafine in breast-feeding women, so it is best to avoid its use in this population. Driving and using machines: No studies have been performed to monitor the effects of Butenafine treatment on the ability to drive and use machines; Discontinuation of the drug if mild adverse reactions occur, usually only discontinuation of Butenafine . In case of severe hypersensitivity or severe allergic reaction, the patient needs to conduct supportive treatment (keep breathing and use Epinephrine, oxygen, use antihistamines, corticosteroids...).